Anti-TNF therapy and immunogenicity in inflammatory bowel diseases: a translational approach

Inflammatory bowel diseases are chronic illnesses that involve intestinal inflammation and are usually diagnosed as Crohn's disease or ulcerative colitis. As these diseases do not have a cure, the goal of treatment is to induce and maintain remission. Monoclonal antibodies have been recognized as the most advanced therapy to avoid complications and reduce the need for surgical approaches. However, although their effectiveness has been proven by several studies, they can trigger the immune system, induce the occurrence of immunogenicity, which may lead to the loss of response and treatment failure. The purpose of this review is to determine what are the main mechanisms involved in IBD; to assess the recommended treatments; to explore the mechanisms of immunogenicity. We also try to explain the detection and describe the existing advances that make possible the clinical application of these approaches.

Automated summary

Inflammatory bowel diseases, including Crohn's disease and ulcerative colitis, are chronic illnesses characterized by intestinal inflammation. Current treatment focuses on inducing and maintaining remission, with monoclonal antibodies considered an advanced therapy to prevent complications and reduce the need for surgery. However, these antibodies may trigger immune responses, leading to potential immunogenicity and treatment failure.